# A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)

> **NCT06245941** · PHASE1,PHASE2 · TERMINATED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 21 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** TQ05105 tablets
- **DRUG:** TQB3909 tablets

## Key facts

- **NCT ID:** NCT06245941
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-05-13
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06245941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06245941, "A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06245941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*